Signaling Pathway News and Research

RSS

Broken heart syndrome arms against epinephrine high

Takotsubo cardiomyopathy, or “broken heart syndrome,” may actually protect the heart from very high levels of epinephrine, suggest results from an animal study.

10 Jul 2012

Conference highlights utility of zebrafish for human disorder studies

Zebrafish, popular as aquarium fish, now have an important place in research labs as a model organism for studying human diseases.

8 Jul 2012

NOTCH1 signaling promotes T-cell acute lymphoblastic leukemia-initiating cell regeneration

Research suggests that patients with leukemia sometimes relapse because standard chemotherapy fails to kill the self-renewing leukemia initiating cells, often referred to as cancer stem cells. In such cancers, the cells lie dormant for a time, only to later begin cloning, resulting in a return and metastasis of the disease.

3 Jul 2012

Imaging PR status may help identify tumor response to endocrine therapy

Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage.

3 Jul 2012

New treatment target against metastatic pancreatic cancer

Detailed analysis of genes expressed in circulating tumor cells (CTCs) -- cells that break off from solid tumors and travel through the bloodstream -- has identified a potential treatment target in metastatic pancreatic cancer.

2 Jul 2012

Study details canonical Wnt signaling pathway

Many lung cancers are driven by mutations in the epidermal growth-factor receptor (EGFR), and so it makes sense that many successful modern treatments block EGFR activity. Unfortunately, cancers inevitably evolve around EGFR inhibition, and patients with lung cancers eventually relapse.

30 Jun 2012

UH receives federal grants to pursue projects related to prostate cancer, diabetes and obesity

Researchers at the University of Houston (UH) have been awarded more than $862,000 in federal grants to pursue projects related to prostate cancer, diabetes and obesity. The U.S. Department of Defense (DOD) and National Institutes of Health (NIH) will fund two new prostate cancer projects, while a third NIH grant will support diabetes and obesity research in the UH Center for Nuclear Receptors and Cell Signaling (CNRCS).

28 Jun 2012

Researchers discover how GLP-2 receptor suppresses hunger and food intake

Researchers have discovered how a hormone in the gut slows the rate at which the stomach empties and thus suppresses hunger and food intake. Results of the animal study will be presented Monday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

De novo somatic gene mutations likely to cause hemimegalencephaly

Hemimegalencephaly is a rare but dramatic condition in which the brain grows asymmetrically, with one hemisphere becoming massively enlarged. Though frequently diagnosed in children with severe epilepsy, the cause of hemimegalencephaly is unknown and current treatment is radical: surgical removal of some or all of the diseased half of the brain.

25 Jun 2012

Grb2 switch controls normal signaling through fibroblast growth factor receptor

Once considered merely a passive link between proteins that matter, Grb2 - pronounced "grab2" - actually lives up to its nickname with its controlling grip on an important cell signaling pathway, scientists at The University of Texas MD Anderson Cancer Center report in the June 22 issue of Cell.

22 Jun 2012

Lead 8A analog can treat osteosarcoma in children

Jiayuh Lin, PhD, and colleagues at Nationwide Children's Hospital have developed a drug to target the most common cancerous bone tumor in children, osteosarcoma, using a version of the FDA-approved drug, Celebrex. The team will soon begin testing the drug using human and canine tumor cell lines thanks to a two-year, $200,000 grant from Alex's Lemonade Stand Foundation for Childhood Cancer.

22 Jun 2012

Review describes new classes of drugs that target androgens in novel ways

Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

21 Jun 2012

Combination therapy may help defeat pancreatic cancer

Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

20 Jun 2012

Single protein determines persistence of viral infection

Scientists from The Scripps Research Institute have shown a single protein can make the difference between an infection clearing out of the body or persisting for life. The results also show where the defects occur in the immune system without the protein and offer the possibility that targeting this signaling pathway could be beneficial for treatment of persistent viral infections in humans.

14 Jun 2012

Scientists discover one of the most important cellular mechanisms behind meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor. A report on the discovery, published in the journal Molecular Cancer Research, could lead the way to the discovery of better drugs to attack these crippling tumors, the scientists say.

14 Jun 2012

NEJM hails vismodegib as ‘the greatest advance in therapy yet seen’ for advanced BCC

Vismodegib, a new skin cancer drug for patients with advanced basal cell carcinoma tested by TGen, Virginia G. Piper Cancer Center at Scottsdale Healthcare and Mayo Clinic, is hailed as "the greatest advance in therapy yet seen" for advanced basal cell carcinoma in an editorial in the New England Journal of Medicine.

14 Jun 2012

Researchers find pathway for origin and growth of the most common form of brain and spinal cord tumor – meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor.

12 Jun 2012

Erivedge drug shows promise against advanced basal cell carcinoma

It's the most common form of skin cancer, but in its advanced stages, basal cell carcinoma has the potential to become disfiguring and life threatening. An international phase 2 study headed by Mayo Clinic led to the recent Food and Drug Administration approval of the first drug of its kind to help advanced basal cell carcinoma patients who have few treatment options.

8 Jun 2012

Researchers identify brain receptor that appears to play a central role in regulating appetite

Researchers at Columbia University Medical Center (CUMC) have identified a brain receptor that appears to play a central role in regulating appetite. The findings, published today in the online edition of Cell, could lead to new drugs for preventing or treating obesity.

8 Jun 2012

Clinical study demonstrates effectiveness of vismodegib in treating BCNS

A revolutionary clinical study has demonstrated the effectiveness of a new drug, vismodegib, in dramatically shrinking and preventing the formation of basal cell skin cancers - the most common cancer in the United States - in patients with basal cell nevus syndrome (BCNS), a rare genetic condition that causes hundreds to thousands of skin cancers primarily treated by surgical removal.

7 Jun 2012